1. Key Insights

2. Executive Summary of Soft Tissue Sarcoma

3. Competitive Intelligence Analysis for Soft Tissue Sarcoma

4. Soft Tissue Sarcoma: Market Overview at a Glance

4.1. Soft Tissue Sarcoma Total Market Share (%) Distribution in 2019

4.2. Soft Tissue Sarcoma Total Market Share (%) Distribution in 2032

5. Soft Tissue Sarcoma: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Soft Tissue Sarcoma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Soft Tissue Sarcoma Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Soft Tissue Sarcoma Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Soft Tissue Sarcoma Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Soft Tissue Sarcoma Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Soft Tissue Sarcoma Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Soft Tissue Sarcoma Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Soft Tissue Sarcoma Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Soft Tissue Sarcoma Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Soft Tissue Sarcoma Treatment and Management

8.2. Soft Tissue Sarcoma Treatment Algorithm

9. Soft Tissue Sarcoma Unmet Needs

10. Key Endpoints of Soft Tissue Sarcoma Treatment

11. Soft Tissue Sarcoma Marketed Products

11.1. List of Soft Tissue Sarcoma Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Soft Tissue Sarcoma Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Soft Tissue Sarcoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Soft Tissue Sarcoma Market Size in 7MM

13.3. Soft Tissue Sarcoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Soft Tissue Sarcoma Total Market Size in the United States

15.1.2. Soft Tissue Sarcoma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Soft Tissue Sarcoma Total Market Size in Germany

15.3.2. Soft Tissue Sarcoma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Soft Tissue Sarcoma Total Market Size in France

15.4.2. Soft Tissue Sarcoma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Soft Tissue Sarcoma Total Market Size in Italy

15.5.2. Soft Tissue Sarcoma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Soft Tissue Sarcoma Total Market Size in Spain

15.6.2. Soft Tissue Sarcoma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Soft Tissue Sarcoma Total Market Size in the United Kingdom

15.7.2. Soft Tissue Sarcoma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Soft Tissue Sarcoma Total Market Size in Japan

15.8.3. Soft Tissue Sarcoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Soft Tissue Sarcoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight